Navigation Links
EnzySurge, Maker of DermaStream(R) Secures US$2.5 Million in Private Capital
Date:12/22/2009

RICHMOND, Virginia and ROSH HA'AYIN, Israel, December 22 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for advanced chronic wound management, announced today that it successfully completed its latest round of funding of US $2.5 million. The round was led by Eli Gilboa, CPA, of Gilboa & Licht, who serves as the company's active chairman at a company valuation of US$18.5 million. To date, the company has raised a total US$10 million. Proceeds will be used to accelerate EnzySurge's sales and marketing efforts in the US during the first half of 2010. The addressable market for the DermaStream product line, global chronic wound care market, is estimated at close to US$4.0 billion annually.

EnzySurge recently announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new SilverStream(TM) solution for prescription use. SilverStream is intended for use under the supervision of a healthcare professional for management and moisturizing of wounds such as stage I-IV pressure ulcers, stasis ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, cuts abrasions and minor skin irritations. The FDA also cleared the DermaSept, an Over-the-Counter version of the SilverStream product, which is intended for the management and moisturizing of minor cuts, minor burns, abrasions and irritated areas.

A single patient use disposable system, the DermaStream product line allows for the continuous streaming of fresh therapeutic solutions, such as the SilverStream solution, enzymatic debridement solutions and cleansing solutions, over the wound bed. The treatment provides constant removal of foreign material, exudate, micro-organisms and debris while creating negative pressure over the wound.

"I'm very pleased with this additional round of funding, says Amir Shiner, Chief Executive Officer. This financing allows us to execute our go-to-market market plan in the US during 2010. We recently completed a multi-center clinical study on venous ulcer patients. The preliminary study results demonstrate safety and preliminary efficacy of the DermaStream product line on venous ulcer patients and will strengthen the DermaStream clinical base of evidence that supports our growing marketing and sales activities in the US."

According to Mr. Shiner, the company operates its US marketing and sales activities from its office in Richmond, VA. "EnzySurge has been exploring strategic partnerships with a number of global wound care player," adds Shiner. "Such partnership may allow us to capitalize on the remarkable opportunities that have been recently opened for us in our markets."

    http://www.dermastream.com


    Contact Details :
    Amir Shiner
    CEO
    Mobile : +972-54-3030294

    Eli Gilboa
    CHAIRMAN (Privet Placement Manager)
    Mobile : +972-54-4570011


SOURCE EnzySurge Ltd


'/>"/>
SOURCE EnzySurge Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medicsight plc
2. HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC
3. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
4. ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists
5. Reportlinker Adds Cardiac Pacemakers - A World Market Analysis
6. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. GeoVax Secures $10 Million Financing Commitment
9. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
10. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
11. ALung Secures $2.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):